

AWARD NUMBER: W81XWH-15-1-0139

TITLE: Polymeric RNAi Microsponge Delivery Simultaneously Targeting
Multiple Genes for Novel Pathway Inhibition of Ovarian Cancer

PRINCIPAL INVESTIGATOR: Michael Birrer

CONTRACTING ORGANIZATION: Massachusetts General Hospital
Boston, MA 02114

REPORT DATE: October 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2016		2. REPORT TYPE Annual		3. DATES COVERED 30 Sep 2015 - 29 Sep 2016	
4. TITLE AND SUBTITLE Polymeric RNAi Microsponge Delivery Simultaneously Targeting Multiple Genes for Novel Pathway Inhibition of Ovarian Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-15-1-0139	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Michael Birrer/ mbirrer@partners.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Massachusetts General Hospital (The General Hospital Corp) 55 Fruit St Boston, MA 02114-2554				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT : The first year of this award included the following tasks Major Task 1 IACUC and ACURO Approval <ul style="list-style-type: none"> Subtask 1 IACUC Approval. Months: 1 - 3 Subtask 2 Acuro Approval. Months: 3 - 6 Milestone(s) Achieved: <i>We obtained the necessary approvals for performing animal experiments</i> Major Task 2: Synthesis and in vitro testing of single component RNAi-MS Subtask 1: Synthesis of single component RNAi-MS. Months: 1-3 Subtask 2: Target product inhibition by single component RNAi. Months: 1-3 Subtask 3: Single component RNAi-MS mediated inhibition of in vitro cancer cell tumorigenic behavior. Months:-4-8 This task is still ongoing we will accomplish by end of this no cost extension year, 7/31/2017. Major Task 3: Synthesis and in vitro testing of multiple component RNAi-MS. Months 4-12. This task is in progress					
15. SUBJECT TERMS Ovarian cancer, RNAi, targeting, pathways, novel therapeutics					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	7	19b. TELEPHONE NUMBER (include area code)

Introduction

Background: Epithelial ovarian cancer (EOC) affects 23,000 women in the US per year. Even though EOC is initially sensitive to platinum and taxane chemotherapy following debulking surgery, 75-80% of women will develop recurrent tumors resistant to conventional therapeutics and die of progressively chemotherapy-resistant tumors. Hence, there is a pressing need to identify novel therapies to which these tumors would be sensitive.

EOCs present amplification/deletion of a large number of genes. A strategy that alters the expression level of multiple genes within a single pathway would be a therapeutic approach with significant biologic/clinical impact. RNAi is a promising approach to turn off or on genetic pathways involved in tumor progression, but the current lack of strategies to deliver RNAi in a safe and effective manner prevents the exploitation of this personalized strategy in cancer therapeutics. Large portions of cytotoxic polymers must be used to deliver a comparatively small amount of RNA molecules, resulting in toxicity and narrowing the therapeutic window for RNAi delivery. A direct consequence of this limitation is that multiple RNAi molecules targeting different products cannot be delivered at efficient doses. **We hypothesize that by developing an efficient system of RNAi delivery, that increases both the quantity and types of RNAi molecules delivered to the tumor, a broad range of targeted therapies for effective treatment of recurrent ovarian cancers can be established.**

The goal of this project is to establish a system for efficient delivery of RNAi to ovarian cancers as a new targeted therapeutic strategy. RNAi will be delivered through a system previously published by our group called “rolling circle transcription (RCT)”. RCT uses a polymerase that enables the formation of large macromolecular species that consist of alternating sequences of sense and antisense siRNA separated by a short, cleavable spacer sequence. The resulting large RNA chains self-assemble into negatively charged porous particles called RNAi microsponges (RNAi-MS), with each microsphere containing tens of thousands of copies of siRNA. Upon delivery to the cytosol, the RNAi-MS are rapidly cleaved to form siRNA hairpins, and the large siRNA payload is liberated. The resulting self-assembled systems enable the delivery of much higher amounts of RNAi (up to 3 orders of magnitude more than traditional vehicles), thus improving siRNA knock-down efficacy while lowering toxicity. In addition, different types of RNAi molecules can be bound within a single microsphere thus allowing targeting multiple factors associated with one pathway.

Dr. Birrer lab has recently identified fibroblast growth factor 18 (FGF18) as a potential therapeutic target for a subset of ovarian cancers. He showed that amplification of the chromosomal region containing FGF18 and over-expression of the protein product leads to poor prognosis. *In vivo* mouse studies indicated that FGF18 over-expression increased tumorigenicity of ovarian cancer cells with low FGF18 expression, whereas treatment with a pan inhibitor of FGF receptors decreased tumorigenicity of cells with high FGF18 expression (Figure 1). FGF18 controlled the migration, invasion, and tumorigenicity of ovarian cancer cells through NFκB activation, which increased the production of oncogenic cytokines and chemokines (Figure 1). This skewed the tumor microenvironment toward enhanced angiogenesis, and augmented tumor-associated macrophage infiltration with polarization to an M2 phenotype that promotes tumor progression. Tumors from ovarian cancer patients had increased FGF18 expression with high microvessel density and M2 macrophage infiltration, confirming our results. Thus, through this award we plan to develop RNAi-MS targeting the FGF18 signaling and test the potential efficacy of this novel siRNA delivering system for the treatment of ovarian cancer.

KEYWORDS: Ovarian cancer, RNAi, targeting, pathways, novel therapeutics

Research Accomplishments

Major Task 1: Major Task 1 IACUC and ACURO Approval. Months 1-6

We have obtained Institutional IACUC approval and DOD ACURO approval to perform experiments in mice aimed at testing our novel therapeutics for the treatment of ovarian cancer. This therapeutics consists in delivering nanoparticles composed of polymeric structures of RNAi molecules that target the FGF18/NfκB pathway. The therapeutics will be tested in human ovarian cancer xenografts obtained by implanting ovarian cancer cells in the peritoneum of immunocompromised nu/nu mice.

Major Task 2: Synthesis and in vitro testing of single component RNAi-MS

RNAi Microsponges are synthesized using means termed rolling circle transcription (RCT) with a polymerase that enables the formation of large macromolecular species that consist of alternating sequences of sense and antisense siRNA separated by a short, cleavable spacer sequence. The resulting large RNA chains self-assemble into negatively charged porous particles we refer to as RNAi microsponges (RNAi-MS), with each microsphere containing roughly a half million copies of siRNA. A single molecular layer of polylysine (PLL) is then applied and is adsorbed onto the RNAi-MS. This process compacts the RNAi-MS to positively charged nanoparticles that are more readily taken up by cells and can deliver up to 3 orders of magnitude more siRNA than equal amounts of a traditional commercial lipid cationic vehicle. In addition, the RNAi-MS are labeled with a dye for visualization of our transfection efficacy. Thus synthesis of RNA-MS requires the following optimization steps:

- 1) Identify the most efficient siRNA sequence for effective inhibition of the specific target
- 2) Identify the optimal polylysine composition for least toxicity and maximum transfection efficacy


During this first year of the award we have encountered multiple difficulties in the RNAi-MS generation process, due to PLL toxicity, and difficulty in achieving inhibition of our targeted FGF18 pathway through lipofectamine-mediated siRNA transfection. Specifically, we aimed at generating two single RNAi-MS, one inhibiting FGF18 while the other targeting its downstream effector FRS2a.

We have designed four different siRNA sequences for each of our targeted molecules, FGF18 and FRS2a and established an optimal transfection protocol for the selected ovarian cancer cell lines: SKOV3 and UCI101. Optimization of the transfection protocol to test the efficacy of these siRNA molecules included:

- i. Cells even plating, to reach 50% at time of transfection;
- ii. Test each siRNA at 30nM and 60nM

- iii. Determine the media composition and volume to maximize siRNA transfection;
- iv. Identify the optimal commercial antibody for detecting our targets on western blot.
- v. Test target protein levels at different time points following transfection

Overall, we achieved maximum transfection efficacy when transfection was performed in subconfluent cells (maximum 50%) with 60 nM siRNA and cells were then grown in reduced media volume (maximum 1 mL/well of a 6 wells plate). Target inhibition peaked at 24 hours after transfection and lasted until 72 hours (Figure 1). Not all the siRNA sequences tested for each gene were able to achieve target inhibition, but we have been able to select an active sequence for FRS2a (Figure 1) and one for FGF18.



We have then proceeded with the generation of the microsponges. Initial experiments testing for depletion of ectopic GFP expression in 293T cells indicated that the best composition of microsponges was achieved by coating the microsponges using polylysine polymers conjugated with the Cy5 fluorescent dye. This allowed decreasing the average size of the microsphere of almost 10 fold, from 10 to 1 micron. In addition, thanks to the presence of the dye, we have established the most efficient transfection protocol for these microsponges. The protocol included generating a condensing solution containing 50 nM microsponges, Cy5-polylysine and lipofectamine. However, the first FRS2a-RNAi-MS generated were extremely toxic (Figure 2) and we could not detect FRS2a inhibition due to low protein yield even at a subeffective dose of 10nM.

We have thus tested whether the toxicity was due to the relatively large size of the polylysine polymer used (25 K) or to the dye, or both. To do that, we have exposed the cells growing in 6 wells plate to each reagent composing the microsponges, including a smaller size (4K) of polylysine, for 48 hours and checked under the microscope the cells for toxicity. The reagents

tested included: FRS2a and FGF18 siRNA, 4 k and 25 k polylysine, Cy5 dye. The data clearly confirmed that toxicity was due to the large polylysine polymer and was sharply decreased when using the 4k polymer. We have thus re-synthesized the microsponges using the 4K polylysine and achieved successful transfection and target inhibition of FRS2a (Figure 3).





Figure 2: Microphotographs of cells 48 hours post transfection with: PBS (control), non specific microsponges (NS1 and NS2), and microsponges targeting FRS2a and FGF18. The images show cells following transfection with 1.2nM, 2.5 nM, 5.0 nM and 10 nM microsponges. All these doses are suboptimal for target inhibition, yet excessive toxicity was already visible with 10 nM.



Results disseminated to communities of interest:

Nothing to report

Actual or anticipated problems or delays and actions or plans to resolve them:

The beginning of this project has been slower than expected due to an unexpected difficulty in identifying functional siRNA sequences, efficient methods of cell transfection, and non toxic composition of the microsponges. However, generation of functional microsponges is the core and the novelty of the whole award. We thus expect to encounter less difficulties moving forward.

IMPACT

Impact on the development of the principal discipline(s) of the project: The microsponges we are generating will constitute a novel tool/therapeutic option for patients with ovarian cancer who have upregulation of the FGF18 signaling pathway.

Impact on other disciplines: Nothing to report

Impact on technology transfer: We anticipate that development of these microsponges will have commercial application.

Impact on society beyond science and technology: Nothing to report